ClinicalTrials.gg

Neoplasms, Unknown Primary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 101 studies for Neoplasms, Unknown Primary across more than 10 countries. 19 are recruiting or about to start. 53 of them are mainly about Neoplasms, Unknown Primary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
52
Recruiting
15
Status unknown
11
Active, not recruiting
7
Terminated
6
Withdrawn
5

Phase

Phase 2
38
Phase 1
18
Phase 3
9
Early Phase 1
1

Where

United States
51
China
9
Denmark
8
United Kingdom
7
Canada
7
Netherlands
5

Who develops what

Add Neoplasms, Unknown Primary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CarboplatinEarlier onlyPhase 4 trial recorded
Evidence
  • NCT03498521 · Hoffmann-La Roche · Phase 2 · comparator · “Carboplatin” · registered Apr 2018
  • NCT00873119 · Valerio Therapeutics · Phase 2 · comparator · “carboplatin, paclitaxel” · registered Mar 2009
Eli Lilly and Company16% of its industry studies00 studies
PaclitaxelEarlier only
Evidence
  • NCT03498521 · Hoffmann-La Roche · Phase 2 · background · “Paclitaxel” · registered Apr 2018
  • NCT00873119 · Valerio Therapeutics · Phase 2 · comparator · “carboplatin, paclitaxel” · registered Mar 2009
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neoplasms, Unknown Primary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 2 open · Antimetabolites 18 · Antimitotic agents 14 · Tyrosine kinase inhibitors (TKIs) 4 · Alkylating agents 4

Coming up

8studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8

Who these studies take

Of the 15 Neoplasms, Unknown Primary studies recruiting now, 10 (67%) set no upper age limit and 1 (7%) stop at 75 or younger. 1 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.

Recruiting studies that take each age, of 15
AgeWomenMen
100 (0%)0 (0%)
1814 (93%)14 (93%)
3015 (100%)15 (100%)
4015 (100%)15 (100%)
5015 (100%)15 (100%)
6515 (100%)15 (100%)
7515 (100%)15 (100%)
8513 (87%)13 (87%)

Across all 101 studies, recruiting or not: 8% stop at 75 or younger and 3% at 65; 8% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 101. Browse all 101 → or search them.